Regeneron Pharmaceuticals (REGN) Wells Fargo 21st Annual Healthcare Conference summary

Financial performance and commercial execution

• Achieved double-digit growth in both revenue and profit, led by strong sales of EYLEA HD, DUPIXENT, and LIBTAYO, each reaching record quarterly sales.

• Completed repayment of the Sanofi development balance, enabling full profit recognition from DUPIXENT and KEVZARA collaborations.

• EYLEA HD now represents 60% of franchise sales, up from 50% in the previous quarter, with significant physician adoption due to label enhancements and cross-indication use.

• DUPIXENT continues robust growth, with under-penetration in key indications and geographies, and is now among the top five global products.

• Commercialization capabilities have strengthened, supporting successful launches and market preparation across multiple therapeutic areas.

Pipeline developments and strategic outlook

• Anticipates pivotal data readouts and regulatory milestones for the C5 franchise, including a PDUFA date for cemdisiran in generalized myasthenia gravis and pivotal data in paroxysmal PNH.

• Interim data expected for geographic atrophy programs, with ongoing pivotal cohort enrollment to inform future study design.

• Early-stage metabolic portfolio progressing, including siRNAs for MASH and antibody programs for POTS, with pivotal obesity and type 2 diabetes studies planned for olatorepatide.

• Expansion of the Sanofi collaboration is under discussion, aiming to extend beyond DUPIXENT and leverage joint commercialization strengths.

• Proprietary genetics and proteomics databases are seen as key differentiators for future AI-driven drug discovery and cost management.

Market dynamics and competitive positioning

• EYLEA HD's growth is attributed to label enhancements, positive physician experience, and strong switching trends from other anti-VEGF products, despite biosimilar competition.

• DUPIXENT's growth potential remains high due to low penetration in several indications, broad age range, and strong safety profile, with ongoing efforts to address competitive threats from long-acting biologics.

• The obesity franchise aims to differentiate through combination therapies addressing both weight loss and cardiovascular health, leveraging PRALUENT and olatorepatide.

• Neurology business unit is launch-ready for cemdisiran, targeting a competitive myasthenia gravis market with focus on efficacy, safety, and convenience.

• Capital allocation remains focused on internal investment, but active evaluation of external opportunities continues, with financial flexibility to pursue value-creating deals.